T-knife Therapeutics
PrivateLast Round
Series B
Aug 2, 2021
Total Funding Raised
$207.18M
Company Overview
T-knife Therapeutics is a biopharmaceutical company that develops next-generation T cell receptor (TCR) engineered therapies to treat solid tumor cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
T-knife Therapeutics Comparables
Compare T-knife Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anocca | 83% | |
| Captain T Cell GmbH | 79% | |
| Immatics N.V. | 79% |
T-knife Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 2, 2021 | ||||
| Series A | Aug 6, 2020 |
Key People
Founding team and executive leadership
T-knife Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Columbus Ventures | Series A |
| RA Capital Management | Series B, Series A |
| Sixty Degree Capital | Series B |
| EQT Life Sciences | Series B |
| Andera Partners | Seed, Series B, Series A |
| Fidelity Management & Research Company | Series B |
| OrbiMed | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
Monthly visitors increased 36% MoM, reaching 2.6K.
- Mar 16, 2026
Phase 1 trial initiated for CRISPR T cell therapy.
T-knife Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about T-knife Therapeutics's valuation, stock price, and market status.
Is T-knife Therapeutics a public or private company?
T-knife Therapeutics is a private company.
What is the current stock price of T-knife Therapeutics?
T-knife Therapeutics is a private company, so its shares have no public market price. Caplight tracks T-knife Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is T-knife Therapeutics worth (valuation)?
Valuation information for T-knife Therapeutics is not publicly available.
Can I buy T-knife Therapeutics stock?
T-knife Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was T-knife Therapeutics's last funding round?
T-knife Therapeutics's most recent funding round was Series B on August 2, 2021.
Who are the main investors in T-knife Therapeutics?
Key investors in T-knife Therapeutics include RA Capital Management, Fidelity Management & Research Company, Versant Ventures.
Will T-knife Therapeutics IPO soon?
No public IPO plans have been announced for T-knife Therapeutics.
How can I track T-knife Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in T-knife Therapeutics's shares on secondary markets.